within Pharmacolibrary.Drugs.ATC.A;

model A10BH03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.67,
    Cl             = 13.3 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.105,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00905,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Saxagliptin is an oral antidiabetic medication used for the treatment of type 2 diabetes mellitus. It is a selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, which increases incretin levels (GLP-1 and GIP), inhibiting glucagon release and increasing insulin secretion. Saxagliptin is approved and widely used today as a second-line therapy for glycemic control.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult human subjects, both male and female, following a single oral 5 mg dose under fasting conditions.</p><h4>References</h4><ol><li><p>Patel, CG, et al., &amp; Boulton, DW (2011). Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. <i>Diabetes, obesity &amp; metabolism</i> 13(7) 604–614. DOI:<a href=&quot;https://doi.org/10.1111/j.1463-1326.2011.01381.x&quot;>10.1111/j.1463-1326.2011.01381.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21332626/&quot;>https://pubmed.ncbi.nlm.nih.gov/21332626</a></p></li><li><p>Upreti, VV, et al., &amp; Boulton, DW (2012). Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women. <i>Diabetes, obesity &amp; metabolism</i> 14(12) 1155–1157. DOI:<a href=&quot;https://doi.org/10.1111/j.1463-1326.2012.01635.x&quot;>10.1111/j.1463-1326.2012.01635.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22776778/&quot;>https://pubmed.ncbi.nlm.nih.gov/22776778</a></p></li><li><p>Boulton, DW, et al., &amp; Patel, CG (2011). Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. <i>Clinical pharmacokinetics</i> 50(4) 253–265. DOI:<a href=&quot;https://doi.org/10.2165/11584350-000000000-00000&quot;>10.2165/11584350-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21348538/&quot;>https://pubmed.ncbi.nlm.nih.gov/21348538</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BH03;
